In-House Versus Outsource: A Decision-Making Guide

In-House Versus Outsource: A Decision-Making Guide

The biologics market is quickly evolving from a focus on developing blockbuster drugs to exploring niche markets with unmet needs. While the changes are exciting, they pose several risks to a molecule’s success as competition intensifies, timelines shorten and capacity challenges emerge. Yesterday’s solutions may not be a perfect fit for today’s molecules.

Authors:
Barry Rosenblatt, PhD President, SME Biotech Consulting
Dave Kenyon, PhD Vice President, Process Sciences Pharma Services Patheon, by Thermo Fisher Scientific

Resource Library

Related Sites

Additional Resources

Strategic CDMO partnerships: Leveraging infrastructure investments and innovation to accelerate biologics development

Advanced therapies and large molecule investments

Five Ways to Get to IND/IMPD Faster

Getting from R&D to IND - Pitfalls to avoid and how to succeed

Growing Your Biopharma: Ten Questions You're Likely to Face From Investors—And How to Respond to Them

5,000L single-use bioreactors: The next generation in biologics manufacturing

A Tale of Two CDMOs: Which Choice Will Your Biopharma Make?

CDMO Timebombs: Five Ways the Wrong Partner Can Lead to Trouble Down the Road

Analytical Considerations For Biopharmaceuticals During Commercialization

Small Pharma, Big Opportunity Infographic

Benefits of 5KL Bioreactor When Outsourcing Late-phase Biologics Drug Substance Manufacturing

Practical Implementation of Innovative and Scalable Technologies to Accelerate Biologics Development and Commercialization: A CDMO Perspective

Saving Development Time with Single Vendor Approach

Leveraging Infrastructure Investments and Innovation to Accelerate Biologics Development

Accelerating Cell Culture Development through Practical Application of Innovation Technologies

Leveraging Innovative Technologies, Best Practices and Strategies to Accelerate Biologics Development and Commercialization

Biologics Overview

Quick to Clinic™ Delivers Phase I Clinical Trial Material, Fast

What You Need to Know About Process Characterization and Validation For Biologic Processes

Choosing the Right CDMO for Late Phase Clinical Trials

Process Characterization: Ready For The FDA?

Biopharma Capabilities Overview

Pharma Services Overview Brochure

In-House Versus Outsource: A Decision-Making Guide

Getting to First-in-Human Clinical Trials: A Make-or-Break Milestone for Small Biopharmas

Implications of Inaccurate Forecasting on Biologics Drug Substance Manufacturing

Biologics Overview: Flexible Biomanufacturing Solutions

So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Case Study: Curbing the Opioid Epidemic with Pacira Pharmaceuticals

Choosing the Best Biomanufacturing Strategy: The Value of a Multi-Pronged Approach

Is Your In-House Strategy Ready for the Uncertainties of Biologic Drug Development?

Managing Demand Uncertainty in Biologics Production

Top 5 Considerations When Looking to Outsource to a Biomanufacturing Partner

The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing

Consultants’ Guide to Flexible Biomanufacturing Solutions

Top Five Risks Facing Your Small Biopharma Clients Today

Challenges, Risks, and Strategies for Biologic Substance Manufacturing

Solutions to Today’s Biomanufacturing Challenges

Multiplexing: Managing Risk with Proven, Single-Use Solutions

© 2021 Thermo Fisher Scientific Inc. All rights reserved. Cookie Use Privacy Terms of Use Modern Slavery Statement

Cookie Use Privacy Terms of Use Modern Slavery Statement

© 2021 Thermo Fisher Scientific Inc. All rights reserved.